TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01073670
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.
Study: NCT01073670
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
Study: NCT00375362
Drug: Nitroderm patch
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02020122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: non active placebo
Study: NCT02416128
Drug: Euphrasia
Normalized name: Euphrasia
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in the treated eye QID X 10 days
Study: NCT02416128
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop in the treated eye QID X 10 days
Study: NCT03482297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo will be given three times a day on the baseline day (placebo)
Study: NCT03281187
Drug: Nasotestt 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.
Study: NCT03030989
Drug: Placebo Wipe
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00090701
Drug: AG2037
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01671072
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride 0.9%, 3.5ml
Study: NCT01690000
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 or 3 mg of melatonin PO each night for 12 months
Study: NCT01697605
Drug: BGJ398
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02205255
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
Study: NCT02205255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02161484
Drug: Ropivacine 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm.
Study: NCT02691013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04704492
Drug: Biological: SM03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0,2
Study: NCT01955772
Drug: Enteral nutrition alanyl-glutamin, Dipeptiven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition versus parenteral nutrition
Study: NCT00546156
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard chemotherapy regimen
Study: NCT01730534
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose (od)
Study: NCT00546156
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard chemotherapy regimen
Study: NCT01647516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02394496
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: as indicated in the Summary Product Characteristic
Study: NCT03395470
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DDI
Study: NCT01493687
Drug: CD5024
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD5024 1% Cream, once daily
Study: NCT00162409
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00089141
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01053962
Drug: SP-304 9.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP-304 9.0 mg
Study: NCT01053962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01163643
Drug: 0.3% BOL-303242-X ophthalmic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.
Study: NCT01163643
Drug: 2% BOL-303242-X ophthalmic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% BOL-303242-X ophthalmic suspension BID for 12 weeks.
Study: NCT03896737
Drug: Daratumumab plus Velcade Cyclophosphamide Dexamethasone
Normalized name: Velcade
DrugBank: Bortezomib D-mannitol (DB16741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
Study: NCT01163643
Drug: Placebo Comparator: Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Vehicle BID for 12 weeks.
Study: NCT01163643
Drug: 1% BOL-303242-X ophthalmic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% BOL-303242-X ophthalmic suspension BID for 12 weeks.
Study: NCT00880061
Drug: IL13-PE38QQR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01163643
Drug: 2% BOL-303242-X ophthalmic suspension AM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.
Study: NCT01163643
Drug: 2% BOL-303242-X ophthalmic suspension PM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.
Study: NCT03171480
Drug: Monoket Pill
Normalized name: Monoket Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-vaginal application of Monoket as a cervical ripening agent for pregnant women undergoing induction of labor
Study: NCT03171480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacy has compounded an identical appearing placebo
Study: NCT01077609
Drug: Intermittent, sub-chronic and chronic Flixonase use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
Study: NCT01077609
Drug: Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
Study: NCT03580590
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet
Study: NCT04141631
Drug: EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~* Hb \< 13g/dL the day before surgery~* Hb ≥ 7g/dL AND ScvO2 \> 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb \< 7g/dL independently of ScVO2 value
Study: NCT00019058
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03699462
Drug: Plasma solution-A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
Study: NCT03699462
Drug: 5% Albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
Study: NCT02833844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of matching placebo QM
Study: NCT01051544
Drug: FVIII/VWF concentrates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
Study: NCT03471442
Drug: General anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia administered as per preference of intra-operative attending anesthesiologist
Study: NCT03471442
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
Study: NCT03471442
Drug: Anesthetics, Local
Normalized name: ANESTHETICS, LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing of this local anesthetic mixture.
Study: NCT01333709
Drug: Induction trichemotherapy - FOLFIRINOX regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
Study: NCT00775840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
Study: NCT00508404
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
Study: NCT04326894
Drug: 25 mg/week oral methotrexate tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00603018
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
Study: NCT05516225
Drug: PBCLN-003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human Milk Oligosaccharide Concentrate
Study: NCT02857530
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: without rhTPO
Study: NCT00720512
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00720512
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03020875
Drug: Per Os Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered acetaminophen.
Study: NCT00038597
Drug: SCH66336
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00046852
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02525744
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00466661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tabs po TID
Study: NCT00742872
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
Study: NCT01070667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
Study: NCT00226668
Drug: placebo hCRF
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
Study: NCT03036384
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5µg sufentanyl
Study: NCT00794638
Drug: SyB L-0501
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
Study: NCT04086212
Drug: EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution
Normalized name: EXTRANEAL 7.5g/100ml Peritoneal Dialysis Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a long dwell exchange for three days.
Study: NCT00461656
Drug: Preoperative conjunctival irrigation with 5% or 1.25% PI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before initiation of surgery, children will have their conjunctival fornices irrigated with 5 ml PI 5% or with 5 ml PI 1.25%
Study: NCT03409107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daprodustat matching placebo will be available as 9 mm or 7 mm film coated tablets. Placebo will be administered once daily via oral route and can be taken without regard to food.
Study: NCT03409107
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy will be administered if ferritin is \<50 Nano gram per milliliter and/or TSAT is \<15 percent.
Study: NCT01176695
Drug: MCT/LCT containing lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: medium chain triglycerides, long chain triglycerides
Study: NCT01968707
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically.
Study: NCT01968707
Drug: 3M CHG/IPA Prep Tint 10.5-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically.
Study: NCT01968707
Drug: 3M CHG/IPA Prep Tint 26-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically
Study: NCT00220649
Drug: gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03451695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
Study: NCT00857077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02161354
Drug: NTC-510 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to one of 3 groups and NTC-510 will be given as a single oral dose of 2.0 mg, a split dose of 2.0 mg followed by 2.0 mg an hour later, or 6.0 mg for acute pain relief (PR) following third molar extraction.
Study: NCT02161354
Drug: Placebo Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to one of 3 groups and placebo capsules will be given as a single oral dose of for acute dental pain following third molar extraction.
Study: NCT02161354
Drug: NTC-510A Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to one of 3 groups where NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction
Study: NCT00391170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01989793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given to those in placebo arm
Study: NCT02395237
Drug: : Amaryl® M IR 2/1000
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04370704
Drug: INCMGA00012.
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCMGA00012 administered intravenously
Study: NCT01621880
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
Study: NCT00005889
Drug: alanine
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02991118
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
Study: NCT00005889
Drug: leucine
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005889
Drug: urea
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02537002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous dose of matched placebo
Study: NCT03858725
Drug: D569 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: D569 Tab. 1T single oral administration under fasting condition
Study: NCT03858725
Drug: CKD-374 5mg Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition
Study: NCT01185743
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo td
Study: NCT03560804
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
Study: NCT02183272
Drug: Intranasal Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
Study: NCT03676504
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 days of cyclophosphamide 500 mg/m\^2/day
Study: NCT04373967
Drug: Victoza®.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Victoza®. Both products will be provided as pen-injector.
Study: NCT04373967
Drug: TQZ2451
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive TQZ2451.Both products will be provided as pen-injector.
Study: NCT02458768
Drug: IVF-M HP Inj.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02458768
Drug: Menopur® Inj.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00402571
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02850822
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen,such as CAG, G-CSF 5-10ug/kg/day on days 4 and 17；Aclacinomycin 7mg/m2/day on days 4 and 11；Cytarabine 20mg/m2/day on days 4 and 17.
Study: NCT04144088
Drug: Wu Ling San
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.
Study: NCT04144088
Drug: Yin-Chen Wu Ling San
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.
Study: NCT04144088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.
Study: NCT02047656
Drug: LFF269
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFF269 capsules twice daily (b.i.d)
Study: NCT02047656
Drug: Placebo to LFF269
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo LFF269 b.i.d for 10 days in healthy volunteers
Study: NCT01935856
Drug: KHK7580
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02287584
Drug: DSP-5423P Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily
Study: NCT02287584
Drug: DSP-5423P Placebo-to-Flex
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSP-5423P Placebo:~DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily
Study: NCT02287584
Drug: DSP-5423P Active-to-Flex
Normalized name: Ed Flex
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSP-5423P Active:~DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily
Study: NCT00106184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1
Study: NCT03403751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion of 0.5 mL/kg of 0.9% saline (volume equivalent to Reltecimod dosing schema) over approximately 10 minutes